English
Back
Download
Clear
All
Quotes
News
Learn
Help
All
US
HK
CN
SG
AU
JP
All
News
Announcements
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh Refresh
Loading
History record
    Latest News
      Quotes More
      News More
      Learn More
      Help More
      Loading
      News More
      Announcements More
      Reports More
      Log in to access Online Inquiry
      Back to the Top

      🟤Watchlist, JANUARY 29,2025, Wednesday. NFA.

      NOTE!
      1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
      2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
      3. Scale out and secure profits.
      4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
      5. I DO NOT give buy or sell advice
      6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
      7. NEVER be a blind follower.

      LASTLY, If you don’t appreciate my watchlist, STAY AWAY and I won’t think twice blocking you. I shun uncouth and toxic people in my life.
      ▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
      $ATAI Life Sciences (ATAI.US)$ PR 1/28 Announces Positive Topline Results from Beckley Psytech's BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder. Study showed sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three months. COH $113M

      $Azul SA (AZUL.US)$ PR AH 1/28 Company concluded its restructuring process initiated in 2024 to solidify its financial position, eliminating US$ 2.1 billion in debt and financial obligations and receiving US$ 525 million in new capital. Also, CEO says merger with Gol will bolster Brazil's aviation industry and may lead to an expansion of Azul's destinations to 200 from 150. No dilution risk

      $BeyondSpring (BYSI.US)$ PR 1/28 U.S. FDA has granted Rare Pediatric Disease and Orphan Drug designations to SEED's ST-01156 molecular glue. This novel agent degrades RBM39, an RNA splicing factor implicated in multiple mechanism-targeted solid tumor indications. Also, It also sold part of its equity interest in its subsidiary,SEED, with $35.4M proceeds. COH $5.8M good for 4.8 months

      $Dermata Therapeutics (DRMA.US)$ PR 1/28 Issuance of New U.S. Patent for Next-Generation Acne Treatment. This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne. SI 20.53%. COH $5M good for 5.4 months

      $Faraday Future Intelligent Electric Inc. (FFIE.US)$ 🟤PR AH 1/28 Receives $30 Million of Previously Committed Financing. Up AH. Low float. SI 39.52% (squeezable). COH $6.6M good for 1.2 months

      $Hyzon Motors (HYZN.US)$ 🟤Delisting January 30 (Thursday). May have pre-delisting pump. Low float. 0 shares LTB.

      $Knightscope (KSCP.US)$ PR 1/28 Partners with U.S. Air Force on Autonomous Security Robots. It is a Phase I SBIR contract to streamline and improve Air Force Installation Security procedures and outcomes. Low float. COH $8.9M good for 4.6 months

      $La Rosa Holdings (LRHC.US)$ PR 1/28 Cancels $2.4M Warrants And Signals Expansion For 2025. The company Strengthens Balance Sheet By Redeeming And Extinguishing A Large Portion Of Outstanding Warrants. Low float.

      $Spectral AI (MDAI.US)$ PR 1/28 Completes Pediatric Enrollment in Emergency Departments for U.S. Burn Pivotal Study. One of the largest domestic burn studies ever conducted, the U.S. Burn Pivotal Study is designed to validate the AI-driven algorithm used by the Company's DeepView™ System for burn indication. This may not be a trial or study result but I consider this a major achievement considering its large scale enrollment. The company will pursue the Novo classification from FDA based on the data gathered from this study. Low float. COH $2.3M good for 2.2 months

      $Mobilicom (MOB.US)$ PR 1/28 Mobilicom's Cybersecure MCU-30 Selected by One of the World's Largest Loitering Munitions Manufacturers (Tier-1 Israel-based defense company) for its Latest Perimeter Protection Drone Fleets. Low float. COH $11.2M good for 24 months

      $NLS Pharmaceutics (NLSP.US)$ 🟤PR 1/28 Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence. CDC reported 105,007 drug overdose deaths - with 90% involving synthetic opioids like fentanyl. SI 46%, CTB 453%, COH $4.3M good for 17.4 months

      $Silexion Therapeutics (SLXN.US)$ 🟤PR 1/28 Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models. The key findings demonstrate that systemic administration of SIL-204 effectively reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis in human pancreatic tumor models. This is one of the deadliest cancer known to men so the tumor reduction is a significant finding. Ran today, but may still gain steam tomorrow. Good volume after hours. Low flow. 0 shares LTB, CTB 524%.

      $60 Degrees Pharmaceuticals (SXTP.US)$ 🟤PR 1/28 Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis. This will be an open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient settings. Low float. Up AH . Low float.

      $Telomir Pharmaceuticals (TELO.US)$🟤 PR 1/28 Announces Breakthrough Results With Telomir-1 showing it fully reverses Copper-Induced oxidative stress in human cell lines. in Human Cell Lines. Note why this is important: Oxidative stress drives aging and is a key factor in diseases like Alzheimer’s, age-related macular degeneration, cardiovascular diseases, cancer, and diabetes. Low float. No cash on hand. High risk.

      $Tevogen Bio Holdings (TVGN.US)$ PR 1/28 Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding. The grant is intended to further Tevogen Bio's mission to develop T cell therapeutics addressing the significant unmet needs of large patient populations for treatment of cancers and viral infections and its AI expansion efforts . Low float. No cash on hand.

      $Zentalis Pharmaceuticals (ZNTL.US)$ 🟤PR AH It announced a strategic restructuring to focus on late-stage development of its WEE1 inhibitor, azenosertib. The company plans a workforce reduction of approximately 40% to be completed in Q2 2025, extending its cash runway into late 2027. NOTE: tomorrow 8AM ET re Phase 2 readout on Azenosertib, their lead product candidate for the treatment of platinum-resistant ovarian cancer. This has history of big move. COH $335M
      ▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
      PREVIOUS NEWS (May still have delayed market reaction)
      $Beamr Imaging (BMR.US)$ 🟤 PR 1/27 There will be an online webinar, "The Future of Video AI - From Infrastructure to Experience, with BMR, Oracle, and NVDIA on January 29 11:30AM ET. This will likely be buy the rumor sell the news so I am expecting a build up tomorrow. Low float. COH $17.64M good for more than 12 months

      $ConnectM Technology Solutions (CNTM.US)$ PR 1/27 Acquires MHz Invensys, Enhancing Wireless Communication Solutions. ConnectM projects an additional $15M revenue from the AMI vertical by 2027. The global AMI market is expected to reach $47.5 billion by 2030, growing at a CAGR of 16.1% from 2024-2030. Low float.

      $Gamehaus Holdings (GMHS.US)$ PR Newly merged China stock (Gamehaus), a technology-driven mobile game publisher. May gain attention post merger and CNY.

      $Hepion Pharmaceuticals (HEPA.US)$ PR AH 1/27 13G filed 9.99%. Up AH. Went up today but still has good volume AH. COH $2.3M good for 1.2 months

      $New Horizon Aircraft (HOVR.US)$ PR 1/27 Compliance News. Relatively Low float. COH $6.8M good for 9.8 months

      $Icon Energy (ICON.US)$ PR 1/27 13G 9.99%. Low float. COH $0.5M. High risk for dilution
      $Lisata Therapeutics (LSTA.US)$ PR 1/23 same as 1/22 PR 1/22 Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma. Study showed 4 CR (complete response- non detectable) is impressive considering this is a very aggressive and deadly cancer. Positive overall survival which is one of the most important metric in trials. It’s badly beaten by shorts. May rebound. Low float. COH $29.5M good for 17.9 months.
      $Richardson Electronics (RELL.US)$ PR AH 1/24 Company is acquired by DirectMed Imaging which strengthens DirectMed Imaging’s Position as the Leading Canon/Toshiba Aftermarket Parts Supplier. Additionally, Richardson Electronics entered into an exclusive 10-year global supply agreement in which Richardson will supply DirectMed with repaired Siemens CT X-ray tubes. Richardson Electronics will also continue manufacturing ALTA CT X-ray tubes for DirectMed for approximately 12 to 18 months. RELL is the global provider of engineered solutions for renewable energy and other power management applications. Low float.

      $Sacks Parente Golf (SPGC.US)$ PR 1/27 ER Revenue is expected to be between $1.1 million - $1.3 million in 4Q24, an increase of 882% at the midpoint of the range from revenue of $117,000 in 4Q23. Full year 2024 revenue expected to increase from $349,000 in FY 2023 to $3.4 million - $3.6 million, representing almost 10-fold growth. Low float. COH $8.4M good for 22 months. Ran today but AH Price over VWAP. May continue PM.

      $Xunlei (XNET.US)$ PR 1/27 Xunlei to Acquire Hupu. XNET is a company providing distributed cloud services. Hupu is China's leading sports media and data platform. Acquisition is for total consideration of 500M RMB. China low float. COH $4.4M.

      $22nd Century (XXII.US)$ AH 1/27 Compliance news. Microfloat. SI 20%. COH $5.9M good for 5.4 months
      ✳️ $Toppoint Holdings (TOPP.US)$ the only one left of post IPO which hasn't rallied. The other 3 ran already: DGNX, DXST, MCTR
      ▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
      POSSIBLE MOMENTUM PLAYS
      (Most are CNY plays)
      $TuanChe (TC.US)$
      $Tonix Pharmaceuticals (TNXP.US)$
      ▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️.
      ▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
      REVERSE SPLIT JAN 29
      $Aclarion (ACON.US)$🟤 ~61K shares (RS Jan 30. May have pre RS spike)
      ▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
      POST RS FOR POSSIBLE POST RS SPIKE

      $Bionano Genomics (BNGO.US)$
      $MiNK Therapeutics (INKT.US)$
      $Inspire Veterinary Partners (IVP.US)$
      $Vincerx Pharma (VINC.US)$
      $Wheeler Real Estate Investment Trust Inc (WHLR.US)$

      ▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️
      Form 4s, 13Gs. 13Ds

      $AIM ImmunoTech (AIM.US)$ 1/21 Form 4 Code P Insider buy. COH $2.6M good for 2.1 months

      $Ardelyx (ARDX.US)$ 1/22 Form 4 insider buy

      $Assembly Biosciences (ASMB.US)$ 12/31 Form 4 insider buying. Low float. COH $97.6M good for 17.3 months.

      $180 Life Sciences (ATNF.US)$ 1/3 13G 4.99. Low float.

      $Chijet Motor (CJET.US)$ 1/21 13G 8.72%. No cash on hand.

      $Cellectis (CLLS.US)$ 1/24 13D/A 44% up from 22% Astra Zeneca

      $KALA BIO (KALA.US)$ 12/31 Form 4 huge insider buying. Low float.

      $Mangoceuticals (MGRX.US)$ 1/22 13G 14.44%

      $NAYA Biosciences (NAYA.US)$ 1/16 16 13Gs 9.99% and 6.9%. Low float.

      $Outlook Therapeutics (OTLK.US)$ 1/22 13D/A 38.6% ownership up from 25%
      ▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️▪️STOCK EDUCATION
      Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
      +63
      25
      Translate
      Report
      219K Views
      Comment
      Sign in to post a comment

      View more comments...

      Spread kindness and love. Life is short. Don’t let greed eat you.
      8225
      Followers
      52
      Following
      94K
      Visitors
      Follow
      Discussing
      Trump 2.0 Era: How will global markets evolve?
      🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
      How will you adjust your portfolio under Trump's tariff impact?
      55%
      45%
      🚀Risk Assets
      🛡️Safe-Haven Assets
      1290 votes
      Reassessing Chinese Assets
      Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.